ESR1 and breast cancer: Persistent promotion of HER2/HER3 signaling due to the overproduction of the HER3 ligand HRG suffices to upregulate IL-8 expression as part of the endocrine-resistant phenotype in ER-positive/HER2-negative breast cancer cells.